生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | EZH2 is the enzymatically active core subunit of the PRC2 complex, which methylates H3K27 and facilitates chromatin compaction and gene silencing. EPZ005687 is a potent inhibitor of PRC2 with IC50 value of 54±5nM (measured by PRC2 enzymatic activity), with selectivity >500-fold over other HMTs, ~50-fold over EZH1. EPZ005687 can specifically inhibit H3K27 methylation. Treatment with EPZ005687 (0.044-5.6uM) for 96h shows a dose-dependent decrease in H3K27me3 in wild-type EZH2 lymphoma cell line OCI-lY19. EPZ005687 can decrease proliferation in a dose (<8.3uM) and time (<11 days) dependent manner in mutant EZH2 lymphoma cells, WSU-DLCL2 (Y641F) and pfeiffer (A677G), but not wild-type cells, OCI-lY19 cell line. Treatment in mutant EZH2 lymphoma cells, WSU-DLCL2 (Y641F), with EPZ005687 (0.2-6uM) for 4 days resulted in a dose-dependent increase of accumulation in G1[1]. Recently, it was found that EPZ005687 (10mg/kg, injected peritoneally, once a week for 4 weeks) can significantly inhibit the development of TAC (Transverse Aortic Constriction) -induced PAH (pulmonary artery hypertension) in an EZH2-SOD1-ROS dependent manner in male balb/c mice (6–8 weeks old) [2]. | ||
作用机制 | EPZ005687 is a SAM-competitive inhibitor of PRC2, which binds in the SAM pocket of the EZH2 SET domain.[1] |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human OCI-LY19 cells | Function assay | 96 h | Inhibition of wild-type EZH2 in human OCI-LY19 cells assessed as reduction of H3K27me3 level after 96 hrs by ELISA assay, IC50=0.08 μM | 25406853 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.85mL 0.37mL 0.19mL |
9.26mL 1.85mL 0.93mL |
18.53mL 3.71mL 1.85mL |
参考文献 |
---|